DK1002092T3 - Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf - Google Patents

Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf

Info

Publication number
DK1002092T3
DK1002092T3 DK99924978T DK99924978T DK1002092T3 DK 1002092 T3 DK1002092 T3 DK 1002092T3 DK 99924978 T DK99924978 T DK 99924978T DK 99924978 T DK99924978 T DK 99924978T DK 1002092 T3 DK1002092 T3 DK 1002092T3
Authority
DK
Denmark
Prior art keywords
hcv
mimotopes
hypervariable region
glycoprotein
applications
Prior art date
Application number
DK99924978T
Other languages
Danish (da)
English (en)
Inventor
Alfredo Nicosia
Armin Lahm
Anna Tramontano
Riccardo Cortese
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of DK1002092T3 publication Critical patent/DK1002092T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99924978T 1998-05-19 1999-05-14 Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf DK1002092T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810756.8A GB9810756D0 (en) 1998-05-19 1998-05-19 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Publications (1)

Publication Number Publication Date
DK1002092T3 true DK1002092T3 (da) 2006-03-06

Family

ID=10832337

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99924978T DK1002092T3 (da) 1998-05-19 1999-05-14 Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf

Country Status (13)

Country Link
US (1) US7034108B1 (zh)
EP (1) EP1002092B1 (zh)
JP (1) JP4593780B2 (zh)
KR (1) KR20010022026A (zh)
CN (1) CN1274387A (zh)
AT (1) ATE308618T1 (zh)
AU (1) AU766610B2 (zh)
CA (1) CA2297408C (zh)
DE (1) DE69928064T2 (zh)
DK (1) DK1002092T3 (zh)
ES (1) ES2251832T3 (zh)
GB (1) GB9810756D0 (zh)
WO (1) WO1999060132A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
WO2001093804A2 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
AU2002222139A1 (en) * 2000-12-09 2002-06-18 Cambridge University Technical Services Limited Hcv vaccines
EP2172552A3 (en) 2001-10-11 2010-07-21 Merck Sharp & Dohme Corp. Recombinant nucleic acids comprising regions of AD6
EP1436397B1 (en) 2001-10-11 2010-05-12 Merck Sharp & Dohme Corp. Hepatitis c virus vaccine
CN1305898C (zh) * 2003-08-22 2007-03-21 中国科学院上海生命科学研究院 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
EP1893636A2 (en) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
US7985734B2 (en) * 2006-06-01 2011-07-26 Yun Cheng Peptides for preventing or treating liver damage
WO2007146975A2 (en) * 2006-06-13 2007-12-21 Athenix Corporation Methods for generating genetic diversity by permutational mutagenesis
AU2007347119B2 (en) 2006-11-29 2012-02-02 BASF Agricultural Solutions Seed US LLC Improved GRG23 EPSP synthases: compositions and methods of use
CN110078800B (zh) * 2019-04-24 2021-01-29 中国人民解放军第二军医大学 合成肽在制备防治肝炎病毒感染药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
CA2162557C (en) 1993-05-12 2004-09-28 Amy J. Weiner Conserved motif of hepatitis c virus e2/ns1 region
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
JPH11124398A (ja) * 1997-10-22 1999-05-11 Japan Energy Corp Ｃ型肝炎ウイルス由来の抗原ペプチドとそれを用いる抗体検査薬

Also Published As

Publication number Publication date
EP1002092A1 (en) 2000-05-24
AU4143599A (en) 1999-12-06
AU766610B2 (en) 2003-10-16
WO1999060132A1 (en) 1999-11-25
CA2297408A1 (en) 1999-11-25
DE69928064D1 (de) 2005-12-08
ES2251832T3 (es) 2006-05-01
JP4593780B2 (ja) 2010-12-08
DE69928064T2 (de) 2006-07-20
EP1002092B1 (en) 2005-11-02
GB9810756D0 (en) 1998-07-15
CN1274387A (zh) 2000-11-22
CA2297408C (en) 2011-06-21
JP2002515249A (ja) 2002-05-28
KR20010022026A (ko) 2001-03-15
US7034108B1 (en) 2006-04-25
ATE308618T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
DE69232906T2 (de) Detektion des Hepatis-C Virus.
NO934542D0 (no) Hepatitt C virus (HCV) polypeptider
NO870412L (no) Peptider.
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
DK0698216T4 (da) Fremgangsmåder til typebestemmelse af hepatitis-C-virus og anvendte reagenser heri
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
NZ518999A (en) Vaccine compositions
NO20051715L (no) HCV assay
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
WO2001093804A3 (en) Hepatitis c virus conjugates
EP0870830A3 (en) Chimera hepatitis C virus antigen
DK0599913T3 (da) Monoklonale antistoffer mod formodet hepatitis C-virus NS5-proteiner og anvendelsesmetoder af samme
GR970300022T1 (en) Peptide capable of being recognised by antibodies recognising the C33 antigen of hepatitis C virus
IT1270941B (it) Peptidi di hcv e loro usi.